Compare AbbVie Inc (ABBV) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Stanley Black & Decker, Inc. — how do they compare? AbbVie Inc trades at $251.78 (market cap $439.59B), while Stanley Black & Decker, Inc. trades at $103.13 (market cap $15.54B). The key difference: AbbVie Inc is far larger — about 28.3× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| ABBV | SWK | |
|---|---|---|
Market Cap | $439.59B | $15.54B |
Sector | Health | — |
52-Week High | $263.58 | $104.00 |
52-Week Low | $197.38 | $62.12 |
Enterprise Value | $503.84B | $19.71B |
Dividend Yield | 2.78% | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $253.54, up 1.44% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust revenue growth driven by Skyrizi and Rinvoq offset Humira declines, though net margins have compressed. The stock is near resistance at $253, with institutional buying and positive clinical news supporting momentum.
Outlook remains positive with a $278.69 consensus price target, but high P/E of 70.27 and looming patent cliffs in the 2030s pose risks. Dividend growth and pipeline advancements offer upside, yet valuation and competitive pressures warrant caution for near-term investors.
Stanley Black & Decker (SWK) trades at $103.11, up 0.46% today, with a bullish technical signal from moving averages but overbought RSI readings near 80. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.57 exceeding expectations by 30%. Recent news highlights a $1 billion U.S. investment plan and strong institutional buying, while fundamentals show improving margins and debt reduction progress.
SWK presents a mixed outlook: positive earnings momentum and strategic initiatives support upside, but valuation appears stretched with a P/E of 25.4 above sector averages. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is cautious with a hold-heavy rating and $93.67 price target below current levels, suggesting limited near-term upside despite operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
